Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jae Pil Shin, MD, PhD
Kyungbuk National University Hospital
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gyeongsang National University Hospital
Jinju, Gyeongsangnam-do, South Korea
- Busan Paik Hospital
Busan, South Korea
- Gospel Hospital
Busan, South Korea
- Haeundae Paik Hospital
Busan, South Korea
- Pusan National University Hospital
Busan, South Korea
- Keimyung University Dongsan Medical Center
Daegu, South Korea
- Kyungpook National University Hospital
Daegu, South Korea
- Yeungnam University Medical Center
Daegu, South Korea
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Apr 2016
- Primary completion
- 30 Sept 2019
- Completion
- 31 Dec 2019
- Last update posted
- 1 Mar 2019
- Registered enrollment
- 48
- Registry id
- NCT02788877
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.